Financial Contrast: NewLink Genetics (NLNK) and Its Competitors
NewLink Genetics (NASDAQ: NLNK) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare NewLink Genetics to similar companies based on the strength of its institutional ownership, valuation, profitability, risk, dividends, analyst recommendations and earnings.
Insider and Institutional Ownership
52.7% of NewLink Genetics shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for NewLink Genetics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Competitors||539||2461||6691||127||2.65|
NewLink Genetics currently has a consensus price target of $25.67, indicating a potential upside of 214.93%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.93%. Given NewLink Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe NewLink Genetics is more favorable than its peers.
Earnings and Valuation
This table compares NewLink Genetics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NewLink Genetics||$35.77 million||-$85.15 million||-3.34|
|NewLink Genetics Competitors||$217.29 million||-$39.39 million||-65.38|
NewLink Genetics’ peers have higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares NewLink Genetics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Competitors||-4,529.52%||-557.70%||-43.05%|
Volatility & Risk
NewLink Genetics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, NewLink Genetics’ peers have a beta of 1.58, indicating that their average share price is 58% more volatile than the S&P 500.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.